Revenue grew 76.0% vs Q1 FY2015
Loss widened by 6.7% vs Q1 FY2015
EPS stagnant at -US$0.08, same as Q1 FY2015
Current Ratio 2.03
Debt to Equity Ratio 0.40
Key takeaways from Conference Call:
1) Revenue achieved record high in Q1 FY2016.
2) US$42 million in manufacturing back log
3) New manufacturing facility has capacity to generate up to US$40 million in revenue
4) Recruitment for Sunrise Phase III Trial on track to complete by year end 2015
5) Possible first look in of Sunrise Phase III Trial in first half of 2016 and second lookin by mid year 2016
6) Breast Cancer Phase II/III Trial to begin by end of 2015
7) Lung Cancer Phase II Trial combining Bavituximab and BMY's Opdivo to begin by end of 2015
8) Design stage for the trial combining Bavituximab and AZN's Durvalumab
From the look of things, I believe the first few months of 2016 have a telling effect on the Share Price. Things will move very fast from there on.
My disclosure: I won shares of PPHM.
No comments:
Post a Comment